Overview

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

Status:
Completed
Trial end date:
2018-11-03
Target enrollment:
Participant gender:
Summary
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
Phase:
Phase 2
Details
Lead Sponsor:
Novan, Inc.
Collaborator:
Premier Research Group plc